Stockscreener 앱 받기
69.72
5.49%
-4.05
시장 영업 전:
70.87
1.15
+1.65%
Novo Nordisk Adr 주식(NVO)의 최신 뉴스
Why Novo Nordisk’s slimmed down stock might be worth a… shot - Finimize
NVO’s Stock Woes: Down -31.04% in 6 Months, Down -31.04% in Just 5 Days - investchronicle.com
Why Novo Nordisk Stock Sank by Nearly 4% Today - The Motley Fool
European Stocks Shine As ADRs Climb Higher - Finimize
After ousting CEO, Novo Nordisk reclaims crown as largest European company - MSN
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
European ADRs Show Resilience In US Market - Finimize
Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat - Morningstar
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize
What Did We Find About Insider Trading At Novo Nordisk ADR (NYSE: NVO)? - Stocksregister
European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up - MSN
Novo Nordisk ADR earnings beat by $5.64, revenue topped estimates - Investing.com Nigeria
Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales - Morningstar
Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales, but Strategy Should Preserve Growth - Morningstar
European ADRs See Mixed Results With Modest Gains - Finimize
Novo Nordisk expects U.S. sales of Wegovy weight-loss drug to recover soon, CEO says - The Globe and Mail
Market news - investments.halifax.co.uk
Novo Nordisk cuts guidance but says generic competition will ease - Sharecast.com
NOVO_B Stock Price and Chart — OMXCOP:NOVO_B - TradingView
Novo Nordisk A/S Common Stock (NY: NVO - FinancialContent
Novo Nordisk Stock Price Today | NYSE: NVO Live - Investing.com
European Stocks Shine In US With ADR Gains - Finimize
0.83%
1.02%
자본화:
|
볼륨(24시간):